Simone Y Loo1, Maria Vutcovici2, Alain Bitton2, Peter L Lakatos2,3, Laurent Azoulay1,4,5, Samy Suissa1,4, Paul Brassard1,4. 1. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. 2. Division of Gastroenterology, McGill University Health Center, Montreal, Quebec, Canada. 3. 1st Department of Medicine, Semmelweis University, Budapest, Hungary. 4. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 5. Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.
Abstract
OBJECTIVES: To explore the trends and the predictors of incident malignant cancer among patients with inflammatory bowel disease [IBD]. METHODS: We identified a cohort of all patients with incident IBD in Quebec, Canada, from 1998 to 2015, using provincial administrative health-care databases [RAMQ and Med-Echo]. Annual incidence rates [IRs] of cancer were calculated using Poisson regression and were compared with those of the Quebec population using standardized incidence ratios [SIRs ]. Temporal trends in these rates were evaluated by fitting generalized linear models. Conditional logistic regression was used to estimate odds ratios [ORs] for predictors associated with cancer development. RESULTS: The cohort included 35 985 patients with IBD, of which 2275 developed cancers over a mean follow-up of 8 years (IR 785.6 per 100 000 persons per year; 95% confidence interval [CI] 754.0-818.5). The rate of colorectal cancer decreased significantly from 1998 to 2015 [p < 0.05 for linear trend], but the incidence remained higher than expected, compared with the Quebec population [SIR 1.39; 95% CI 1.19-1.60]. Rates of extraintestinal cancers increased non-significantly over time [p = 0.11 for linear trend]. In the IBD cohort, chronic kidney disease [OR 1.29; 95% CI 1.17-1.43], respiratory diseases [OR 1.07; 95% CI 1.02-1.12], and diabetes mellitus [OR 1.06; 95% CI 1.01-1.11] were associated with an increase in the incidence of cancer. CONCLUSIONS: The decreasing rates of colorectal cancer suggest improved management and care in IBD. Further studies are needed to explore the impact of comorbid conditions on the risk of cancer in IBD.
OBJECTIVES: To explore the trends and the predictors of incident malignant cancer among patients with inflammatory bowel disease [IBD]. METHODS: We identified a cohort of all patients with incident IBD in Quebec, Canada, from 1998 to 2015, using provincial administrative health-care databases [RAMQ and Med-Echo]. Annual incidence rates [IRs] of cancer were calculated using Poisson regression and were compared with those of the Quebec population using standardized incidence ratios [SIRs ]. Temporal trends in these rates were evaluated by fitting generalized linear models. Conditional logistic regression was used to estimate odds ratios [ORs] for predictors associated with cancer development. RESULTS: The cohort included 35 985 patients with IBD, of which 2275 developed cancers over a mean follow-up of 8 years (IR 785.6 per 100 000 persons per year; 95% confidence interval [CI] 754.0-818.5). The rate of colorectal cancer decreased significantly from 1998 to 2015 [p < 0.05 for linear trend], but the incidence remained higher than expected, compared with the Quebec population [SIR 1.39; 95% CI 1.19-1.60]. Rates of extraintestinal cancers increased non-significantly over time [p = 0.11 for linear trend]. In the IBD cohort, chronic kidney disease [OR 1.29; 95% CI 1.17-1.43], respiratory diseases [OR 1.07; 95% CI 1.02-1.12], and diabetes mellitus [OR 1.06; 95% CI 1.01-1.11] were associated with an increase in the incidence of cancer. CONCLUSIONS: The decreasing rates of colorectal cancer suggest improved management and care in IBD. Further studies are needed to explore the impact of comorbid conditions on the risk of cancer in IBD.
Authors: Angela Rocchi; Eric I Benchimol; Charles N Bernstein; Alain Bitton; Brian Feagan; Remo Panaccione; Kevin W Glasgow; Aida Fernandes; Subrata Ghosh Journal: Can J Gastroenterol Date: 2012-11 Impact factor: 3.522
Authors: Luc Biedermann; Nicolas Fournier; Benjamin Misselwitz; Pascal Frei; Jonas Zeitz; Christine N Manser; Valerie Pittet; Pascal Juillerat; Roland von Känel; Michael Fried; Stephan R Vavricka; Gerhard Rogler Journal: J Crohns Colitis Date: 2015-06-26 Impact factor: 9.071
Authors: Rachel Denholm; Joachim Schüz; Kurt Straif; Isabelle Stücker; Karl-Heinz Jöckel; Darren R Brenner; Sara De Matteis; Paolo Boffetta; Florence Guida; Irene Brüske; Heinz-Erich Wichmann; Maria Teresa Landi; Neil Caporaso; Jack Siemiatycki; Wolfgang Ahrens; Hermann Pohlabeln; David Zaridze; John K Field; John McLaughlin; Paul Demers; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Benjamin Kendzia; Susan Peters; Thomas Behrens; Roel Vermeulen; Thomas Brüning; Hans Kromhout; Ann C Olsson Journal: Am J Respir Crit Care Med Date: 2014-09-01 Impact factor: 21.405
Authors: Siddharth Singh; Sajan Jiv Singh Nagpal; Mohammad H Murad; Siddhant Yadav; Sunanda V Kane; Darrell S Pardi; Jayant A Talwalkar; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2013-05-02 Impact factor: 11.382